PrimaryCareNOW offers the same high-quality medical education clinicians have come to expect at our in-person conferences, in an all-new, all-digital format.
This full day of virtual education will provide you with evidence-based sessions that span the diverse therapeutic areas that touch primary care, provide opportunities for interactive Q&A, and offer timely medical updates to keep you informed on the most current clinical strategies relevant to your daily practice.
Earn up to 6.50 AMA PRA Category 1 Credits™ and ABIM Medical Knowledge MOC Points, or 5.50 AANP contact hours during one full day of FREE online education.
Your registration includes the full day, but feel free to join the sessions that work with your schedule.

Agenda

  CME/CE Accredited Session

Non CME/CE Session
Sponsored by Industry

Click For Session Details
Session Times Listed in ET

8–9am ET

Gastroenterology

Evidence-Based Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Stepping Up Therapy to Improve Outcomes

Philip Schoenfeld, MD, MSEd, MSc

This activity will provide an evidence-based approach to the diagnosis and management of irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC), with minimal diagnostic testing. The faculty will describe evidence-based treatment guidelines and discuss the efficacy of over-the-counter and prescription agents prioritized within the guidelines. This will help you navigate the progress from patient education to diet plus over-the-counter agents to prescription agents.

Philip Schoenfeld, MD, MSEd, MSc

Philip Schoenfeld, MD, MSEd, MSc

Chief, Gastroenterology Section John D. Dingell VA Medical Center, Detroit, MI

Supported by Allergan and Ironwood Pharmaceuticals, Inc.; Salix Pharmaceuticals, Inc.

9:10–10:10am ET

Endocrinology

The Heart of the Matter: Primary and Secondary Prevention of Cardiovascular Disease in T2DM

Charles Vega, MD, FAAFP | Archana R. Sadhu, MD, FACE

Adults with type 2 diabetes mellitus (T2DM) have a two- to four-fold increase in risk for cardiovascular (CV) morbidity and mortality. This session cuts to the heart of primary and secondary prevention in this population, presenting recent data on antihyperglycemic medications with proven cardiovascular benefit in the context of updated management algorithms. Individualized treatment is critical to the success of these treatment plans. The faculty will help you optimize adherence through shared decision-making tactics that account for CV risk factors, comorbidities, and patient preferences.

Charles Vega, MD, FAAFP

Charles Vega, MD, FAAFP

Health Sciences Clinical Professor, UC Irvine Department of Family Medicine, Assistant Dean for Culture and Community Education, UC Irvine School of Medicine; Executive Director, UC Irvine Program in Medical Education for the Latino Community, UC Irvine School of Medicine Irvine, CA

Archana R. Sadhu, MD, FACE

Archana R. Sadhu, MD, FACE

Director, System Diabetes Program; Houston Methodist Hospital, Director, Transplant Endocrinology Houston Methodist Hospital, Houston, TX; Assistant Professor of Medicine, Weill Cornell Medical College, New York, NY; Adjunct Assistant Professor, Texas A!M Health Science Center, Dallas Campus, Dallas, TX

Supported by Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

10:20–11:20am ET

Neurology

A Head Start on Migraine: Emerging Approaches to Acute Management

Rashmi B. Halker Singh, MD, FAHS, FAAN | Jessica Ailani, MD, FAHS, FAAN | M. Susan Burke, MD, FACP

With the latest on new and emerging approaches treatment and the most up-to-date patient-centered strategies, this talk will give you a head start on managing acute migraine. Faculty will illustrate the features of acute migraine to help you distinguish it from other headache types and use interactive patient cases to impart practice-changing takeaways about patient management.

Rashmi B. Halker Singh, MD, FAHS, FAAN

Rashmi B. Halker Singh, MD, FAHS, FAAN

Headache Fellowship Program Director, Assistant Professor of Neurology, Mayo Clinic, Scottsdale, AZ

Jessica Ailani, MD, FAHS, FAAN

Jessica Ailani, MD, FAHS, FAAN

Director, Medstar Georgetown Headache Center; Professor of Clinical Neurology, Medstar Georgetown University Hospital, Georgetown, MD

M. Susan Burke, MD, FACP

M. Susan Burke, MD, FACP

Clinical Associate Professor of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Senior Advisor, Lankenau Medical Associates, Lankenau Medical Center, Wynnewood, PA

Supported by Allergan

11:25am–12:10pm ET

Industry Theater

Selecting a First-Choice Therapy for Systolic HF: Meeting the Burden of Proof

Javed Butler, MD, MPH, MBA

This program will highlight a different approach to the treatment of heart failure with reduced ejection fraction (HFrEF). By targeting a mechanism of action aligned to pathophysiologic pathways, it is possible to reduce patient mortality and morbidity, while providing a proven safety and tolerability profile to help provide confidence in selecting your first-choice therapy for patients with HFrEF.

Javed Butler, MD, MPH, MBA

Javed Butler, MD, MPH, MBA

Chairman and Professor, Department of Medicine, University of Mississippi, Jackson, MS

Sponsored by Novartis

12:15–1:15pm ET

Cardiology

Clinical Considerations on Lipid Management of ASCVD in the New Era

Harold E. Bays, MD | Eliot A. Brinton, MD

Providing practical information in an informative format focused on lipid management of ASCVD in the New Era, learners will be provided with important changes in ASCVD guidelines, recognition of elevated triglyceride levels as a target for therapy, a review of clinical trials that recently made a difference in lipid management, practical considerations on using lipid-modifying therapies, and the latest on omega-3 fatty acids for ASCVD.

Harold E. Bays, MD

Harold E. Bays, MD

Eliot A. Brinton, MD

Eliot A. Brinton, MD

Supported by Amarin Pharma Inc.

1:20–2:20pm ET

Pulmonology

Severe Asthma in Primary Care: New Strategies for Management

Gerald W. Smetana, MD | Christopher H. Fanta, MD

The most recent CDC report estimates an asthma prevalence of 7.9% in the U.S. Although patients with severe asthma make up only 3-10% of the total asthma population, they account for a substantial proportion of asthma morbidity and health expenditures. With the emergence of new biologic therapies targeting cytokines involved in pathogenesis of asthma, severe asthma is no longer considered the “refractory” disease of yesteryear. This session offers guidance on distinguishing characteristics pertinent to individualizing asthma treatment, such as subtype, phenotype, and endotype as well as biomarkers and other measures of assessment that identify patients with severe eosinophilic asthma. Using expert guidelines, the faculty will discuss how to apply these individual factors to treatment management and alleviate the burden of asthma in your practice.

Gerald W. Smetana, MD

Gerald W. Smetana, MD

Professor of Medicine, Harvard Medical School, Boston, MA; Clinician Educator, Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Boston, MA

Christopher H. Fanta, MD

Christopher H. Fanta, MD

Professor of Medicine, Harvard Medical School, Boston, MA; Director, Partners Asthma Center, Member, Pulmonary and Critical Care Division, Brigham and Women's Hospital, Boston, MA

Supported by GlaxoSmithKline

2:30–3:30pm ET

Infectious Disease

Managing Influenza: Practical Strategies For Primary Care

Paul E. Sax, MD | Daniel A. Solomon, MD

Is influenza going viral in your practice? This session on influenza diagnosis and management will improve how you respond when annual fluctuations in vaccine efficacy expose your patients to risk of serious illness. Through interactive patient cases, the faculty will demonstrate how to identify and treat patients with suspected influenza, including patients at high risk for complications. These practical, evidence-based strategies will help you to use antiviral medications effectively and reduce the burden of influenza.

Paul E. Sax, MD

Paul E. Sax, MD

Clinical Director, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA; Professor of Medicine, Harvard Medical School, Boston, MA

Daniel Solomon

Daniel Solomon, MD

Associate Physician, Brigham and Women's Hospital; Professor of Medicine, Harvard Medical School

Supported by Genentech

3:40–4:10pm ET

Infectious Disease

COVID-19 Panel Discussion

Paul E. Sax, MD | Daniel A. Solomon, MD | Pamela Kushner, MD, FAAFP

These troubling times require communication among specialists and primary care. In this COVID-19 panel, primary care and infectious disease faculty will team up to discuss the most pressing and frequently asked questions about this disease and its complications.

Paul E. Sax, MD

Paul E. Sax, MD

Clinical Director, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA; Professor of Medicine, Harvard Medical School, Boston, MA

Daniel Solomon

Daniel Solomon, MD

Associate Physician, Brigham and Women's Hospital; Professor of Medicine, Harvard Medical School

Pamela Kushner, MD, FAAFP

Pamela Kushner, MD, FAAFP

Clinical Professor, University of California Irvine Medical Center; Director, Kushner Wellness Center, Los Alamitos, CA

4:15–4:50pm ET

Industry Theater

Thinking Beyond Glycemia: The Importance of Managing Heart Failure Risks in Type 2 Diabetes

Dr. Michael Cobble

We will examine the risk of heart failure (HF) among patients with type 2 diabetes (T2D) and explore evidence-based risk reduction strategies that you can incorporate into your practice. We will discuss the results of the DECLARE trial, the largest cardiovascular (CV) outcomes trial to study hospitalization for HF risk reduction in patients with T2D and CV disease or multiple CV risk factors. We'll also discuss the results of the landmark DAPA-HF trial that support FARXIGA being the FIRST and ONLY FDA-approved sodium-glucose cotransporter 2 inhibitor (SGLT2) for patients with HF with reduced ejection fraction (HFrEF) with and without T2D.

Dr. Michael Cobble

Dr. Michael Cobble

Director and Clinician, Canyons Medical Center Sandy, Utah

Sponsored by AstraZeneca

4:15–5:00pm ET

Industry Theater

A Deeper Dive into the Use of Myrbetriq® (mirabegron) in Patients 65 and Older with OAB Symptoms of Urge Urinary Incontinence, Urgency, and Urinary Frequency

David Staskin, MD

In this session, we will discuss the clinical impact and physiology of overactive bladder as well as the latest perspectives on management and treatment.

David Staskin, MD

David Staskin, MD

Attending in Urology, St. Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, MA

Sponsored by Astellas Pharma US, Inc.

Faculty

Jessica Ailani, MD, FAHS, FAAN
Harold E. Bays, MD
Eliot A. Brinton, MD
M. Susan Burke, MD, FACP
Christopher H. Fanta, MD
Rashmi B. Halker Singh, MD, FAHS, FAAN
Pamela Kushner, MD, FAAFP
Archana R. Sadhu, MD, FACE
Paul E. Sax, MD
Philip Schoenfeld, MD, MSEd, MSc
Daniel A. Solomon, MD
Gerald W. Smetana, MD
Charles Vega, MD, FAAFP